Trial Profile

The Efficacy of Cabozantinib in Advanced SAlivary Gland Cancer Patients, a Phase II Clinical Trial

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary)
Indications Adenoid cystic carcinoma; Carcinoma; Salivary gland cancer
Focus Therapeutic Use
Acronyms Cabo ASAP

Most Recent Events

14 Dec 2021 Results evaluating efficacy and safety of cabozantinib in patients with R/M SGC with c-MET expression published in the European Journal of Cancer
31 May 2020 Status changed from recruiting to discontinued according to results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.
31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com